Epizyme Announces Conference Call to Discuss Corporate Updates
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 15, 2018--Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that management will host a conference call to discuss corporate updates today at 8:30 a.m. ET.
To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 5172457. A live webcast will be available in the investor section of the company’s website at www.epizyme.com. The webcast also will be archived for 60 days following the call and presentation.
About Epizyme, Inc. Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and combination therapy in relapsed and front-line disease. The company is also developing a novel G9a program with its next development candidate, EZM8266, which is targeting sickle cell disease. By focusing on the genetic drivers of disease, Epizyme’s science seeks to match targeted medicines with the patients who need them. For more information, visit www.epizyme.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181115005067/en/
Erin Graves, (617) 500-0615
Monique Allaire, (617) 895-9511
THRUST Strategic Communications
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL
SOURCE: Epizyme, Inc.
Copyright Business Wire 2018.
PUB: 11/15/2018 06:35 AM/DISC: 11/15/2018 06:35 AM